Navigation Links
Ore Pharmaceutical Holdings Announces Name Change and Reverse/Forward Stock Split to be Effective June 10, 2011
Date:6/6/2011

CAMBRIDGE, Mass., June 6, 2011 /PRNewswire/ -- Ore Pharmaceutical Holdings Inc. ("Ore") announced today that, pursuant to the authorization granted by the stockholders of Ore, the Board of Directors of Ore (the "Board") approved and authorized a 1-for-10,000 reverse stock split (the "Reverse Stock Split") of Ore's common stock, $0.01 par value (the "Common Stock"), such that stockholders owning fewer than the amount necessary to receive at least one share of post-split Common Stock (the "Cashed Out Stockholders"), and remaining stockholders holding fractional shares after the Reverse Stock Split, will have such pre-split shares cancelled and converted into the right to receive certain cash consideration, immediately followed by a 10,000-for-1 forward stock split of the Common Stock (the "Forward Stock Split" and together with the Reverse Stock Split, the "Reverse/Forward Stock Split"). The Reverse/Forward Split is expected to be effective June 10, 2011. It is anticipated that the Common Stock will begin trading on the Pink Sheets on a post-split basis at the opening of trading on June 13, 2011 under its current symbol "ORXE.PK".

As previously announced, at the 2011 Annual Meeting of Stockholders of Ore, stockholders approved a name change of Ore from "Ore Pharmaceutical Holdings Inc." to "Ore Holdings, Inc." Ore intends to effect the name change concurrently with the Reverse/Forward Stock Split.

No fractional shares of Common Stock will be issued as a result of the implementation of the Reverse/Forward Split.  Instead, BNY Mellon, our transfer agent, will aggregate all fractional shares of Cashed Out Stockholders and any fractional shares of remaining stockholders after the Reverse/Forward Split and sell them as soon as practicable after the effective time at the then prevailing prices on the open market, on behalf of those stockholders who would otherwise be entitled to receive a fractional share.  We expect that the transfer agent will conduct the sale in an orderly fashion at a reasonable pace and that it may take at least several days to sell all of the aggregated fractional shares of our Common Stock.  After the transfer agent's completion of such sale, stockholders will be entitled to receive a cash payment from the transfer agent in an amount equal to their respective pro rata shares of the total net proceeds of that sale.

Ore intends to treat shares of Common Stock held by stockholders in "street name," that is, through a bank, broker or other nominee, in the same manner as stockholders whose shares of Common Stock are registered in their names.  Banks, brokers and nominees will be asked to effect the Reverse/Forward Split for the underlying beneficial owners holding the Common Stock in "street name."  However, these banks, brokers and nominees may have different procedures for processing the Reverse/Forward Split.  Stockholders who hold their shares in "street name" should ask their broker, nominee or agent to determine how they expect the Reverse/Forward Split will affect their shares of Common Stock. Please refer to the Proxy Statement relating to the 2011 Annual Meeting of Stockholders that was previously mailed to stockholders for more information regarding the Reverse/Forward Stock Split.

As previously reported, Ore has suspended its SEC registration and no longer provides financial or other information through SEC filings. Ore intends to continue to provide quarterly and annual financial information by posting such information on its web site, www.orepharma.com.

To ensure the preservation of the Company's net operating loss, our Certificate of Incorporation limits the ability of stockholders from acquiring more than five percent of our outstanding stock.

Ore Pharmaceutical Holdings Inc. is currently focused on developing and monetizing its current portfolio of pharmaceutical assets, which includes four clinical stage compounds in-licensed from major pharmaceutical companies.


'/>"/>
SOURCE Ore Holdings Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Aeolus Pharmaceuticals, Inc. Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
2. Onyx Pharmaceuticals to Present at the Goldman Sachs 32nd Annual Global Healthcare Conference
3. Wake Forest Baptist Medical Center and Cornerstone Pharmaceuticals Present Interim Data From Phase I Trial of CPI-613 in Acute Myeloid Leukemia
4. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
5. Pacira Pharmaceuticals, Inc. Appoints Two Life Sciences Industry Veterans to Its Board of Directors
6. Vanda Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
7. Syndax Pharmaceuticals Announces Issuance of US Patent for Entinostat
8. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
9. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Jefferies 2011 Global Healthcare Conference on June 9, 2011
10. Isis Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
11. Jazz Pharmaceuticals Announces Presentation at the Jefferies 2011 Global Healthcare Conference in New York on June 8
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... 2017 On Friday, benchmark US ... closed the trading session up 0.19%; the Dow Jones ... was down 0.08%. US markets made broad based gains ... in green. Pre-market today, Stock-Callers.com reviews these four Medical ... WMGI), Amedica Corporation (NASDAQ: AMDA), MiMedx Group Inc. (NASDAQ: ...
(Date:3/27/2017)... 2017  Impax Laboratories, Inc. (NASDAQ: IPXL)today announced that ... Bisaro as Impax,s President and Chief Executive Officer ... 27, 2017. Mr. Bisaro will succeed J. Kevin ... Chief Executive Officer since December of 2016. ... experience, Mr. Bisaro, 56, is an accomplished global business ...
(Date:3/27/2017)... 2017 Arena Pharmaceuticals, Inc. (NASDAQ: ... small molecule drugs across multiple therapeutic areas, today announced that ... will present a corporate update at the 16th Annual Needham ... conference will take place April 4-5, 2017 at the Westin ... , NY.  A live audio webcast of ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... In just ... EcoQube Frame vertical micro-veggies garden on Kickstarter . Surpassing the $100,000 milestone ... with nearly 2,000 consumers (and counting) already backing the campaign. , “We ...
(Date:3/24/2017)... ... March 24, 2017 , ... On June ... ERISA Benefit Claims Litigation seminar in Chicago, Illinois. She will present on: ... of cases litigated under ERISA involve claims for long-term disability benefits. This ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... ) announced their partnership to prep patients for colonoscopy at the HyGIeaCare® Center ... in 87th Ave., Miami, FL. , The HyGIeaCare® Prep, cleared by ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Finding Christ Through ... a devotional journal chronicling the writer’s path toward true communion with God. “Finding ... God #TruthwithGrace” is the creation of published author Lea Michelle Johnson, a follower ...
(Date:3/24/2017)... ... 2017 , ... “The Communion of Saints: A Pastor’s Potpourri ... congregations across the United States. “The Communion of Saints” is the creation ... served congregations in seven states throughout his long career of devotion to the ...
Breaking Medicine News(10 mins):